Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 11, 2024PLOS Global Public HealthOpen Access

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants

View Full Paper
Ask AI
Bookmark
Share

Authors

CRCatherine RiouJBJinal N. BhimanYGYashica Ganga

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Riou et al. (2024) studied this question.

synapsesocial.com/papers/68e6f83cb6db64358767250ehttps://doi.org/10.1371/journal.pgph.0002703
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study2024 · 3 citations
  2. 2Twelve-month follow-up of immunogenicity and safety of fractional and standard booster doses of the Pfizer-BioNTech COVID-19 vaccine in adults primed with ChAdOx1, BBIBP-CorV, or GAM-CoV-Vac: a randomised controlled trial2025 · 1 citations
  3. 3Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults2026
  4. 4Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial2024 · 1 citations
  5. 5Fractional versus standard BNT162b2 boosters after non-mRNA priming in Mongolia: 24-month immunogenicity and safety evidence from a randomised controlled trial2025